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 2009 Elsevier Ltd. All rights reserved.1. Introduction Several fluorescent or radiolabeled AnxV derivatives have al-Apoptosis, or programmed cell death, plays an essential role in
the development and maintenance of a multicellular organism and
contributes to normal physiology and pathology.1
Abundant apoptosis occurs in several pathologies2 as in the case
of organ rejection3 and cardiovascular4 and neurodegenerative dis-
eases.5 Insufficient apoptosis can be seen in malignant processes.6
Therefore, some new anti-cancer therapies focus on induction of
apoptosis. Resistance to apoptosis can be a cause of therapy fail-
ure.7 Imaging of therapy induced apoptosis offers a new way to as-
sess tumor response directly and in an early stage of therapy,8 in
this way allowing an optimal individualized treatment strategy.
One of the hallmarks of cells going into apoptosis is the exter-
nalization of the phospholipid phosphatidylserine (PS) at the cell
membrane.9 Annexin A5 (AnxV A5), a 36-kDa human protein,
shows Ca2+-dependent binding to negatively charged phospholipid
surfaces and was discovered as vascular anticoagulant protein
(VAC-a or AnxV). The anticoagulant activity is based on the high-
affinity for PS.10,11 These characteristics make a derivative of AnxV
a suitable candidate for imaging of apoptosis.ll rights reserved.
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.be (A. Verbruggen).ready been studied.12–15 Technetium-99m radiolabeled hydrazino-
nicotinamide-AnxV (HYNIC-AnxV) has been proposed for
molecular imaging of apoptosis and first clinical data of 99mTc-HY-
NIC-AnxV have already been published.16–18 However, the target-
to-background activity ratio is rather low.19–21 Conjugation of HY-
NIC to AnxV is usually done by coupling N-succinimidyl-HYNIC to
amino groups of the lysine residues. This rather random coupling
results in a not clearly defined product as any of the 21 lysine res-
idues can be targeted. As shown by Tait et al. all four domains of
AnxV are required for optimal uptake in apoptotic tissues. There-
fore caution is necessary in amine-directed labeling strategies that
affect multiple residues on the same protein molecule. Previous
studies have shown that site-specific labeling methods can consid-
erably improve sensitivity for detecting cell death.22,23
Recently our group has developed a novel second generation
AnxV derivative with a single cysteine residue at its concave site.24
This cys-AnxV allows site-specific conjugation of different radio-
metal binding ligands via sulfide formation at the cysteine residue
through thiol chemistry. In this way, the introduced chelator is
located at a well defined position outside the binding region of
the protein, thus not affecting its binding properties. We have
derivatized this so-called ‘second generation’ cys-AnxV in different
ways. Reaction with maleimide-HYNIC yielded HYNIC-cys-AnxV
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designed cys-AnxV with the already known AnxV, which also used
the HYNIC approach for labeling with 99mTc.24 Coupling with
maleimide-DTPA offered the possibility to radiolabel the resulting
DTPA-cys-AnxV with 99mTc-tricarbonyl (99mTcðCOÞ3þ). The
99mTcðCOÞ3þ moiety is known for its excellent kinetic stability
and can easily be prepared using an IsoLink kit from Covidien.25,26
In an alternative approach labeling with 99mTcðCOÞ3þ was per-
formed on cys-AnxV that contained an N-terminal His-tag with
six histidine residues. A discussion about potential ligands for
labeling with the 99mTcðCOÞ3þ moiety and the use of a His-tag
can be found elsewhere.27–29 Biechlin et al. recently described
advantages of a labeling of AnxV with 99mTcðCOÞ3þ.30 But also their
approach (a reaction between free amino residues of lysine and 2-
iminothiolane) introduced a chelating group unspecifically as seen
for N-succinimidyl-HYNIC, contrary to the site-specific conjugation
we demonstrate here for the second generation AnxV.
The three novel 99mTc-labeled AnxV derivatives were all stud-
ied in cell binding experiments on Jurkat T-cells, treated with ion-
omycin. Biodistribution was studied in normal mice as well as in
a mouse model for apoptosis (anti-Fas mAb).31 Based on these
experiments the most promising tracer was chosen to demon-
strate imaging of apoptosis with lSPECT and to study specific
binding.
2. Experimental
2.1. Second generation AnxV derivates
The mutant second generation AnxV was developed by site di-
rected mutagenesis at the University of Maastricht. Glutamine at
position 2 was replaced by a cysteine residue and cysteine at posi-
tion 315 was replaced by serine. The resulting protein with one
accessible cysteine residue at position 2 was conjugated with che-
lating ligands through thiol chemistry. The reaction with 5-
maleimido-2-hydraziniumpyridine hydrochloride (maleimide-HY-
NIC, Abgent, San Diego, CA, USA) formed HYNIC-cys-AnxV (1).
DTPA-cys-AnxV (2) was formed by reaction of cys-AnxV with
maleimide-functionalized diethylene triamine pentaacetic acid
(maleimide-DTPA, Abgent). His-tagged cys-AnxV (3) was prepared
by cloning cDNA of cys-AnxV into pQE30 (Qiagen, KJ Venlo, The
Netherlands) in frame and transforming it in E. Coli JM109 with
the cloned vector. This resulted in cys-AnxV with six histidine ami-
no acids on the N-terminal side of the protein (i.e., at the concave
side outside the PS binding region of AnxV). His-tagged cys-AnxV
was purified from the bacteria using Ni–NTA technology (GE
Healthcare-Amersham Pharmacia, Uppsala, Sweden).32 Then free
cysteine was derivatized with maleimide-biotin to offer the possi-
bility for additional histological avidin–biotin staining and to pre-
vent the formation of disulfides.
2.2. Liquid chromatography
Radiolabeled cys-AnxV derivatives were analyzed by size exclu-
sion chromatography (BioSep-SEC-S3000 column, 300 mm  7.8
mm, Phenomenex, Bester, Amstelveen, The Netherlands) using
0.01 M phosphate buffer (pH 7) as mobile phase at a flow rate of
1 ml/min (isocratic). The eluate was monitored for ultraviolet
(UV) absorbance (Merck Hitachi LV 4000, Burladingen, Germany)
at 254 nm and for radioactivity using a NaI(Tl) scintillation
detector.
The main peak (retention time (tR) = 11.7 min) was isolated and
analyzed by sodium dodecylsulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE). The protein was stained with Coomassie
brilliant blue R-250 (CBB) and the labeled compound was detected
with a STORM 840 Phosphor Imager (Molecular Dynamics,Sunnyvale, CA, USA), confirming a size of 36 kDa for the labeled
compound.
2.3. 99mTc-HYNIC-cys-AnxV (99mTc-1)
Labeling of HYNIC-cys-AnxV with technetium-99m was done in
a sealed 10-ml nitrogen flushed glass vial. 300 ll of [99mTc]per-
technetate solution (800–1600 MBq) from an UltraTechnekow
99Mo/99mTc-generator (Covidien, Petten, The Netherlands) was
mixed with 16 ll of 0.02 M citrate buffer, pH 6, 16 ll tricine solu-
tion (30 mg/ml in water) and 14 ll SnCl2 solution (1 mg
SnCl22H2O/ml in 0.05 M HCl). Finally, 50–60 lg of HYNIC-cys-
AnxV was added and the mixture was incubated at room temper-
ature for 30 min.
Purification and buffer exchange were done with Micron Ultra-
cel YM-10 centrifugal filters (Millipore, Brussels, Belgium) (centri-
fugation at 12,000 rpm for 15 min followed by two rinse steps with
0.2 ml of 0.9% saline), yielding 99mTc- HYNIC-cys-AnxV (99mTc-1) in
0.9% saline solution.
2.4. 99mTc(CO)3-DTPA-cys-AnxV (99mTc(CO)3-2)
The 99mTcðCOÞ3þ precursor was prepared by adding 1 ml of
[99mTc]pertechnetate solution (1800–2500 MBq) to an IsoLink kit
(Covidien, Petten, The Netherlands) which then was heated at
90 C for 20 min. 99mTcðCOÞ3þ precursor solution (400 ll) was ad-
justed to pH 7.5 with 1 M HCl and added to 50–60 lg DTPA-cys-
AnxV. The solution was incubated at 37 C for 1 h under a stream
of nitrogen to reduce the total volume of the reaction mixture.
Purification was done as for 99mTc-HYNIC-cys-AnxV to obtain
99mTc(CO)3-2 in 0.9% saline solution.
2.5. 99mTc(CO)3-HIS-cys-AnxV (99mTc(CO)3-3)
The 99mTcðCOÞ3þ precursor solution was prepared as described
above (pH 7.5) and 400 ll of it was added to 50–60 lg his-cys-
AnxV. The solution was incubated at 37 C for 1 h under a stream
of nitrogen to reduce the total volume of the reaction mixture.
Purification was done as for 99mTc-HYNIC-cys-AnxV to obtain
99mTc(CO)3-3 in 0.9% saline solution.
2.6. Stability tests
Samples of 99mTc-1, 99mTc(CO)3-2 and 99mTc(CO)3-3 were tested
for their plasma stability. The purified tracers (in 100 ll 0.9% saline
solution) were mixed with 1 ml of human plasma and the mixtures
were kept at 37 C. One to four hours later the composition was
checked with size exclusion chromatography (SEC). For the
99mTc(CO)3-complexes (99mTc(CO)3-2 and 3) a competition reaction
with histidine was performed. An excessive amount of histidine
(10 mM) was incubated with 99mTc(CO)3-2 and with 99mTc(CO)3-
3 for 1 h after which the mixtures were analyzed using SEC-HPLC.
2.7. In vitro binding assay
Binding capacity of the three 99mTc-labeled cys-AnxV products
to PS was checked in vitro with ionomycin treated Jurkat cells.33,34
Jurkat T-lymphocyte cells were cultured in RPMI 1640 medium
with glutamax I, 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (P/S). Culture plates were incubated at 37 C in
humidified air with 5% carbon dioxide, and kept in logarithmic
phase by routine passage every 2–3 days. Cells were counted with
a bürker abacus. Cells were centrifuged at 300g for 3 min before
being resuspended in fresh medium (10 mM Hepes, pH 7.4;
150 mM NaCl; 5 mM KCl; 1 mM MgCl2; 1 mg/ml BSA) at
106 cells/ml. Cells were incubated for 10 min with ionomycin
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intracellular calcium concentration up to 1 lM, nearly 10 times
higher than that seen during apoptosis, and a massive PS external-
ization.34 Threefold (n = 3) ionomycin treated cells (5  105) and
threefold (n = 3) non-treated cells were incubated for 15 min with
radiolabeled AnxV (50 ng) in an Eppendorf tube. Afterward the
Eppendorf tubes were centrifuged for 2 min at 1000g. The superna-
tant was removed from the pellet and the activities were measured
using a gamma counter. The percentage of cell-bound activity was
expressed as the percentage of radioactivity in the pellet to the to-
tal radioactivity. Ratios of radioactivity in treated cells compared to
radioactivity in non-treated cells were calculated.
2.8. Animals
Studies in animals were conducted under a protocol approved
by the ethics committee for animal experiments of the University
of Leuven. For the biodistribution experiments and for the FAS-
mediated hepatic apoptosis model normal wild type NMRI mice
were used.
2.9. Biodistribution studies
Biodistribution studies were performed in normal NMRI mice
after tail vein injection of 750–1800 kBq purified 99mTc-labeled
cys-AnxV under isoflurane anesthesia. Animals were sacrificed at
1 h or 4 h pi (3–4 per time point). Organs were weighed and their
radioactivity measured in an automated NaI(Tl) gamma counter
(Wallac Wizard, Turku, Finland). Uptake is expressed as percentage
of injected dose (% ID)/organ and % ID/g of organ.
2.10. In vivo model of Fas-mediated hepatic apoptosis
Fas is a death receptor belonging to the tumor necrosis factor
(TNF) receptor gene family. The ‘death inducing’ Fas ligand binds
to three Fas receptors on the surface of a target cell resulting in a
clustering of the receptors’ death domains (DDs). Then the cyto-
solic adapter protein FADD is recruited which activates the initia-
tor caspase-8, inducing apoptosis through the effector caspases.35
Intravenous injection of an anti-Fas monoclonal antibody (mAb)
in mice induces rapid and massive apoptosis in the liver.31 NMRI
mice were injected intravenously (iv) under isoflurane anesthesia
with purified hamster anti-Fas mAb (7–10 lg of anti-Fas mAb
per mouse, Jo2, BD Pharmingen, Erembodegem, Belgium). 90 min
later mice (n = 3) were iv injected with 750 kBq of 99mTc-labeled
cys-AnxV (99mTc-1, 99mTc(CO)3-2 or 99mTc(CO)3-3). Parallel non-
treated mice (control, n = 3) were injected with the same activity
of radioactive tracer. All animals were sacrificed and dissected
1 h pi and the activity of the weighed organs was measured in an
automated NaI(Tl) gamma counter to calculate the percentage of
ID. Data were expressed as % ID/organ or % ID/g of organ.
Part of the liver was frozen for autoradiography, the other part
fixed in 6% formaldehyde for paraffin embedding and histological
staining. Autoradiographs were recorded from frozen coronal sec-
tions of liver tissue (30 or 50 lm thick) using a phosphor storage
screen (Canberra-Packard, Meriden, CT, USA), exposed overnight
in a cassette (Kodak, Zaventem, Belgium). The exposed screen
was then read using a Cyclone plus storage phosphor system (Stor-
age Phosphor System, Perkin-Elmer, Downers Grove, IL, USA).
Five-micrometer sections were cut from paraffin embedded liv-
ers for histological staining. Standard hematoxylin and eosin (H&E)
staining was performed. In H&E stained slices apoptotic cells are
defined as small cells with dense chromatin (condensation) or in
a later stage through the formation of apoptotic bodies. Immuno-
staining was performed with caspase-3 antibody (Cell Signaling,
Bioké, Leiden, The Netherlands). Also terminal deoxynucleotidyltransferase biotin-dUTP nick end labeling (TUNEL) was performed.
All histological stainings were scored semi-quantitatively and the
fraction of stained cells was expressed as a percentage of the total
number of liver cells per defined field of view.
Additionally immunostaining of the excised liver tissue using a
polyclonal antibody against AnxV (Hyphen Biomed, Villejuif,
France) was performed to show specific binding of injected
99mTc-labeled AnxV to the plasma membrane of cells with apopto-
tic morphology.
2.11. In vivo imaging of Fas-mediated hepatic apoptosis
Images were acquired using a standard SPECT camera (E-cam,
Siemens Medical Systems, Hoffman Estates, IL, USA). The camera
was equipped with two pinhole collimators having multi-pinhole
removable plates optimized for focused mouse imaging with high
sensitivity.36 The plates have seven holes with a diameter of
1.5 mm. The intrinsic resolution of the detectors is 4 mm and the
spatial resolution is 1.2 mm thanks to the magnification of the pin-
holes.37 Acquisition was completed in 35 min with 64 projections
taken over 360 in a step-and-shoot mode (30 s per projection an-
gle). During reconstruction images were corrected for scatter and
decay. Further post-correction for the injected dose and the weight
of the mouse delivered standardized uptake values (SUVs). To en-
able image comparison, the images were clipped to the same
maximum.
Two NMRI mice were imaged 1 h after injection of 15 MBq of
99mTc(CO)3-3 (=baseline lSPECT). After two days the same mice
were treated with anti-Fas mAb (7 lg) and 90 min later 15 MBq
of 99mTc(CO)3-3 was injected. lSPECT was performed 1 h later
(=post-treatment lSPECT). Blocking of PS binding to apoptotic
hepatocytes was investigated by pre-injection of cold AnxV. Two
NMRI mice were treated with anti-Fas and 60 min later 2 mg of
cold unmodified AnxV was injected to block specific binding and
to confirm thereby the specificity of 99mTc-labeled cys-AnxV up-
take in the liver. 99mTc(CO)3-3 was injected 30 min later and after
1 h lSPECT images were acquired (=blocking lSPECT). The mice
were then sacrificed under anesthesia, radioactivity in the dis-
sected liver was measured and autoradiography performed.
2.12. Statistical analysis
All values are shown as mean ± SD. Statistical significance be-
tween two groups was tested by unpaired Student’s t-test using
the software STATISTICA 6.0 (StatSoft, Groningen, The Nether-
lands). A 2-tailed value of p < 0.05 was considered to be statisti-
cally significant.
3. Results and discussion
3.1. Radiolabeling and stability
Radiolabeling yield for 99mTc-1 was P85%. Radiochemical
impurities eluting from the column later than radiolabeled AnxV
such as 99mTc-tricine-citrate (tR = 13.5 min) and [99mTc]pertechne-
tate (tR = 21 min) could not be avoided under optimized condi-
tions. However, an efficient purification method with YM-10
centrifugal filters was introduced to isolate the labeled product
(>98% purity). 99mTc(CO)3-2 and 99mTc(CO)3-3 both had radiochem-
ical yields >90% (Fig. 1), opening up favorable perspectives for the
development of a (clinical) kit. Unconjugated 99mTc(CO)3 precursor
(tR = 13.5 min) was removed by centrifugation resulting in prod-
ucts with a purity >98%.
99mTc-1 remained unchanged as a single compound after 4 h in
plasma. After 1.5 h in plasma 70% of -99mTc(CO)3-2 was still pres-
ent. A small peak was formed which eluted before that of 99mTc-
Figure 1. SEC-HPLC chromatogram of the reaction mixture after labeling of his-cys-AnxV with 99mTc(CO)3 (A). >98% of the activity elutes in the form of 99mTc(CO)3-3
(tR = 11.7). The plasma stability of 99mTc(CO)3-3 after 2 h is shown in the lower chromatogram (B).
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time points in plasma were not checked for these tracers. The com-
petition reaction with an excess of histidine showed a shift of at
least 30% of the 99mTc-label from the DTPA-cys-AnxV to histidine.
99mTc(CO)3-3 remained unchanged in plasma, as shown by the
single peak on SEC-HPLC after 2 h in plasma (Fig. 1). 99mTc(CO)3-
3 remained also unchanged in the presence of an excess of histi-
dine, demonstrating the excellent stability of the compound. These
results suggest that DTPA is not an ideal chelating ligand for the
99mTcðCOÞ3þ core in this setup, while 99mTc(CO)3-3 was found to
be a remarkably stable complex.
3.2. In vitro binding assay
In vitro binding characteristics of 99mTc-1, 99mTc(CO)3-2 and
99mTc(CO)3-3 were studied to prove that the PS binding capacity
is maintained after derivatization and radiolabeling of the respec-
tive AnxV derivatives under the described conditions. All threetracers were found to have a significantly higher uptake in ionomy-
cin treated cells compared to non-treated cells (Fig. 2).
99mTc-1 had twice the percentage of radioactivity (ratio of
2 ± 0.1) in the pellet for the treated cells (44.3 ± 6.4%) compared
to non-treated cells (22.1 ± 2.5%) (p = 0.005) (Fig. 2).
99mTc(CO)3-2 had twice the percentage of radioactivity (ratio of
2.2 ± 0.2) in the pellet for the treated cells (31.2 ± 7.6%) compared
to non-treated cells (14.3 ± 3.6%) (p = 0.01) (Fig. 2).
99mTc(CO)3-3 had more than three times the percentage of
radioactivity (ratio of 4.2 ± 0.6) in the pellet for the treated cells
(50 ± 5.7%) compared to the non-treated cells (12 ± 0.8%)
(p = 0.003) (Fig. 2). These results demonstrate that the derivatiza-
tion and labeling of AnxV did not disturb PS binding for the three
radiotracers. Although 99mTc(CO)3-3 looks more promising the
experiment is limited to draw a final conclusion. It is remarkable
that the controls show high and different radioactivity in the pellet.
The high radioactivity is most likely due to non-specific sticking of
AnxV to the walls of the Eppendorf tube. We used a simple method
Figure 2. Histogram representation of in vitro binding experiment. The percentage
of radioactivity in the pellet is shown for 99mTc-1, 99mTc(CO)3-2 and 99mTc(CO)3-3 in
non-treated cells (control) and after treatment of the Jurkat cells with ionomycin
(treated). For all three tracers the percentage of radioactivity in the pellet is
significantly increased for the treated cells in comparison to control cells.
Table 2
Liver uptake of 99mTc-(1), 99mTc(CO)3-(2) and 99mTc(CO)3-(3) in normal and anti-Fas
treated NMRI mice (n = 3) at 1 h pi expressed as % ID/g. Rate of apoptosis assessed
using H&E staining, caspase-3 staining and TUNEL in normal and anti-Fas treated
livers
Normal Anti-Fas
% ID/g of 99mTc-(1) 5.2 ± 1.3 15.3 ± 4.4
% ID/g of 99mTc(CO)3-(2) 4.8 ± 0.4 7 ± 0.7
% ID/g of 99mTc(CO)3-(3) 6.8 ± 0.8 28.9 ± 3.4
% Apoptotic cells with H&E 0.3 ± 0.1 18.3 ± 4.0
% TUNEL positive 0.8 ± 0.3 20.9 ± 7.4
% Caspase-3 positive 0.3 ± 0.1 63.8 ± 4.2
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sive experiment would be necessary to measure the PS affinity
which was beyond the scope of the current sudy.38
3.3. Biodistribution in healthy mice
Biodistribution of 99mTc-1, 99mTc(CO)3-2 and 99mTc(CO)3-3 was
determined in normal NMRI mice at 1 and 4 h pi. All 99mTc-tracers
were cleared mainly via the urinary tract (Table 1). A faster urinary
excretion was shown for 99mTc(CO)3-3 compared to 99mTc(CO)3-2
and 99mTc-1. The cortical kidney uptake shown for 99mTc-1 on
autoradiography (results not shown) and for 99mTc(CO)3-3 on
lSPECT (Fig. 5) results from high PS expression in the cortex of
the kidneys.39 This was already proposed by Blankenberg who also
suggested the possibility of non-specific uptake of low-molecular
weight proteins by the proximal renal tubule cells as noted in stud-
ies of radiolabeled peptides and antibody fragments.14,40,41
Hepatobilliary excretion was found for all three 99mTc-tracers.
There was no significant change in liver uptake of the 99mTc-tracers
from 1 to 4 h after injection. 99mTc-1 uptake in the liver after 4 h
was significantly lower than that of 99mTc(CO)3-2 and
99mTc(CO)3-3 (Table 1). A clear stomach uptake was seen for
99mTc-1 which suggests a partial oxidation of 99mTc and formation
of 99mTcO4
. This was not observed for both 99mTc(CO)3 tracers.
Blood clearance was fastest for 99mTc-1. 99mTc(CO)3-2 and
99mTc(CO)3-3 stayed longer in the blood although their residual
retention in blood decreased gradually from 1 to 4 h. An advantage
of fast clearance is the resulting low background activity, but aTable 1
Biodistribution of 99mTc-(1), 99mTc(CO)3-(2) and 99mTc(CO)3-(3) in normal NMRI mice 1 an
% ID/g 99mTc-(1)
1 h pi 4 h pi 1 h pi
Kidneys 59.2 ± 12.1 47.2 ± 6.3 70.2 ±
Liver 5.2 ± 1.3 3.7 ± 0.6 7.5 ±
Spleen 3.4 ± 1.1 3.6 ± 0.9 5.6 ±
Lungs 3.5 ± 0.6 1.4 ± 0.2 4.2 ±
Heart 1.3 ± 0.3 0.5 ± 0.1 1.7 ±
Intestines 1.3 ± 0.3 1.7 ± 0.1 1.2 ±
Stomach 8.3 ± 2 4.6 ± 1.6 0.6 ±
Blood 1 ± 0.5 0.5 ± 0.1 3.8 ±longer circulating tracer might have more chance of binding the
target as in case of 99mTc(CO)3-2 and 99mTc(CO)3-3.
A recently published study by Fonge et al. demonstrated a sim-
ilar biodistribution for first generation 99mTc-HYNIC-AnxV and the
second generation 99mTc-HYNIC-cys-AnxV.24 However, the biodis-
tribution results of the present study for 99mTc-1 at 1 h after injec-
tion differ from the data given in Fonge’s study. The labeling
method was the same in both studies, but in the present study a
centrifugal purification method was introduced as compared to
SEC purification in the study of Fonge et al.24 A decreased uptake
in liver, lungs, spleen and heart was seen for 99mTc-1 and also a
lower retention in blood after 1 h (0.96 ± 0.49% ID/g compared to
2.9 ± 0.2% ID/g). SEC-purification necessitates manipulation of the
protein during a longer time and reduction of the volume after col-
lection of the desired HPLC peak by gentle heating under a stream
of nitrogen. These conditions might result in colloid formation and
therefore more lung uptake. Also the different ionic strength of the
solvents used for SEC purification and centrifugal purification
(0.01 M phosphate buffer vs 0.9% saline) might contribute to the
differing results, especially as the salt concentration increases
when the volume is reduced. Purification using centrifugal filters
thus may have the advantage of decreasing background activity.
3.4. Fas-mediated hepatic apoptosis
Previous studies demonstrated the lethal effect of anti-Fas mAb
on hepatocytes.31 However, ex vivo quantification of apoptosis by
H&E, TUNEL and caspase-3 has not yet been reported before and
are shown in Table 2. Both TUNEL and H&E detect DNA fragmenta-
tion and apoptotic bodies occurring late in the process of apoptosis
and give similar levels of apoptosis after treatment (±20%) (Fig. 3C,
D, G, and H). Caspase-3 is activated early in the process and there-
fore immunostaining with caspase-3 antibody showed a greater
number of apoptotic cells after treatment (60%) (Fig. 3K and L).
These results demonstrate that treatment with anti-Fas mAb leads
to a fast hepatic apoptosis with more than half of the hepatocytes
becoming apoptotic within 150 min. Immunostaining of AnxV
(brown color) revealed little AnxV presence in normal liversd 4 h post-injection (pi) expressed as % ID/g (n = 3 or 4)
99mTc(CO)3-(2) 99mTc(CO)3-(3)
4 h pi 1 h pi 4 h pi
7.6 44.3 ± 0.5 42.4 ± 5.1 37 ± 9.6
1.9 6.4 ± 0.3 6.7 ± 0.9 8.4 ± 3
3.4 2.6 ± 1.2 5 ± 1.4 3.1 ± 0.9
0.2 2.9 ± 0.1 11.5 ± 3.7 9.5 ± 5.7
0.03 1.2 ± 0.1 1.6 ± 0.4 1.4 ± 0.6
0.3 1.3 ± 0.1 0.8 ± 0.1 2 ± 0.2
0.5 0.9 ± 0.3 1 ± 0.2 1.1 ± 0.4
0.7 2.1 ± 0.1 2.9 ± 0.4 1.6 ± 0.5
Figure 3. Autoradiography images of liver of normal and anti-Fas mAb treated mice after injection of 99mTc-1 (A and B), 99mTc(CO)3-2 (E and F), 99mTc(CO)3-3 (I and J).
Stainings of normal (C, G, and K) and anti-Fas treated (D, H, and L) livers with H&E, TUNEL and caspase-3, respectively.
Figure 4. Immunostaining of liver of normal mouse (A) and anti-Fas treated mouse (B) using a polyclonal antibody against AnxV-V (brown color). This visualizes the binding
of AnxV to the membrane of apoptotic cells.
M. De Saint-Hubert et al. / Bioorg. Med. Chem. 18 (2010) 1356–1363 1361(Fig. 4A) while anti-Fas treated livers showed AnxV binding to the
cell membranes of apoptotic cells (Fig. 4B).
Uptake of 99mTc-1 and 99mTc(CO)3-2was significantly (p = 0.003
and p = 0.007, respectively) higher in liver of anti-Fas mAb treated
animals compared to controls (Table 2). Autoradiography showed a
3.6 and 1.5 times higher liver uptake of 99mTc-1 and 99mTc(CO)3-2,
respectively, after treatment (Fig. 3A, B, E, and F).
99mTc(CO)3-3 showed the highest liver uptake of the three
99mTc-labeled AnxV derivatives in anti-Fas mAb treated animals.
It was significantly increased (p < 0.0001) from 6.8 ± 0.8% ID/g to
28.9 ± 3.4% ID/g (Table 2). Autoradiography also revealed a 4.8
times higher liver uptake of 99mTc(CO)3-3 after treatment as com-
pared to control mice (Fig. 3I and J). These results show the ability
of 99mTc-labeled second generation AnxV mutants to bind to apop-
totic cells in vivo, with the best result for 99mTc(CO)3-3 (Fig. 3). The
99mTc(CO)3-3 revealed a 61% higher affinity for apoptosis in com-
parison to the first generation 99mTc-HYNIC-AnxV which was
evaluated in the same anti-Fas model and showed an only 2.6times higher liver uptake after treatment.24 As the 99mTc(CO)3-3
compound has a higher bloodpool value (discussed under Section
3.3) it should be noted that the target-to-blood ratios are in the
same order of magnitude compared to 99mTc-1. Although it was
not reflected in our images this could be approached by delaying
the time between 99mTc(CO)3-3 injection and acquisition. In the
current setting we could not investigate this with the anti-Fas
model since animals die approximately 4 h after treatment.
lSPECT images acquired after administration of 99mTc(CO)3-3 to
normalmice showed very high uptake in the kidneys (especially coro-
nal uptake) and some liver uptake (Fig. 5A and B). Mice treated with
anti-Fas mAb displayed mainly liver uptake and much less activity in
the kidneys 1 h after 99mTc(CO)3-3 injection (Fig. 5C and D). The
pre-injection of cold unmodified AnxV caused a decreased uptake in
the apoptotic liver (Fig. 5E and F) as compared to the liver of anti-Fas
treatedmicenotpre-treatedwithcoldAnxV(Fig.5CandD).Thisproves
that PS binding sites were saturated and 99mTc(CO)3-3 uptake in the
apoptotic liver was exclusively due to the protein characteristics.
Figure 5. lSPECT imaging 1 h after 99mTc(CO)3-3 injection in mice. Image values are expressed as SUV and the same scaling is used for the different acquisitions. Imaging was
performed before treatment (A–C), after treatment with anti-Fas (D–F) and after treatment with anti-Fas and pre-injection of cold AnxV (G–I). Transversal (A, D, and G),
coronal (B, E, and H) and sagittal (C, F, and I) views are shown. Liver, kidneys and bladder are indicated by L, K, B.
1362 M. De Saint-Hubert et al. / Bioorg. Med. Chem. 18 (2010) 1356–13634. Conclusion
Second generation cys-AnxV derivatives were successfully
labeled to form three apoptosis imaging agents (99mTc-1,
99mTc(CO)3-2 and 99mTc(CO)3-3). 99mTc(CO)3-3 showed the best re-
sults with respect to radiolabeling yields (kit formulation possible),
stability, distribution in the body (fast urinary elimination, low
stomach uptake, etc.) and in vivo affinity for hepatic apoptosis.
The low target-to-background activity ratio experienced in clinical
imaging applications with first generation 99mTc-HYNIC-AnxV19–21
might be improved with this second generation 99mTc(CO)3-3. This
can open new opportunities for an early tumor response assess-
ment in cancer patients.
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